John Chiminski at JPM20 (Jeff Rumans)

Catal­ent amps up plans to man­u­fac­ture J&J's Covid-19 vac­cine, adding vial fill­ing line in Italy

A lit­tle more than a year af­ter Catal­ent CEO John Chimin­s­ki ac­quired Bris­tol My­ers Squibb’s man­u­fac­tur­ing fa­cil­i­ty in Anag­ni, Italy, the big CD­MO is us­ing it to amp up sup­plies of J&J’s Covid-19 vac­cine.

On Wednes­day the phar­ma gi­ant an­nounced an ex­pand­ed deal to lay on added man­u­fac­tur­ing ca­pac­i­ty in­volv­ing vial-fill­ing, in­spec­tion, la­bel­ing, and pack­ag­ing ser­vices. Catal­ent plans to scale up a new, high speed vial fill­ing line to in­crease pro­duc­tion for J&J’s one-shot vac­cine, which re­cent­ly won a ma­jor OK in the US. The sprawl­ing plant en­com­pass­es 300,000 square feet of space.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.